Carolyn Bodnar

Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer

Evelina Bertranou, Carolyn Bodnar, Viktor Dansk et al. · Journal of Medical Economics · 2017 · 40 citations

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI

Helen Mann, Frank Andersohn, Carolyn Bodnar et al. · Clinical Drug Investigation · 2017 · 20 citations · Full text

Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer

K. Tong, Kimberly Mislick, Warren H. Schonfeld et al. · ClinicoEconomics and Outcomes Research · 2014 · 10 citations · Full text

Performance Goals for an Adjunct Diagnostic Test to Reduce Unnecessary Biopsies After Screening Mammography: Analysis of Costs, Benefits, and Consequences

Christoph I. Lee, Mark Bensink, Kristin Berry et al. · Journal of the American College of Radiology · 2013 · 10 citations

Reduce Unnecessary Biopsies, Medical Imaging, Cancer Detection +12